Why Skyrizi from AbbVie is quietly reshaping psoriasis treatment

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 13:05. Details in the imprint.

With Skyrizi, AbbVie puts a biologic on the table that promises many adults with moderate to severe plaque psoriasis something very concrete - visibly clearer skin after a few weeks and then only four injections a year to keep it that way.

How Skyrizi is meant to work

Skyrizi is a monoclonal antibody that targets the inflammatory messenger interleukin-23, a key driver in plaque psoriasis according to AbbVie’s prescribing information. It is given as a subcutaneous injection at week 0, week 4 and then every 12 weeks thereafter.

In clinical studies, a high proportion of patients achieved 90 percent skin clearance (PASI 90) after 16 weeks, and many reached completely clear skin (PASI 100), as summarized in pivotal trials such as UltIMMa-1 and UltIMMa-2. This “clear or almost clear” goal is now standard in modern psoriasis therapy.

Dosing rhythm and everyday life

For patients, the dosing rhythm is one of Skyrizi’s quiet strengths. After the loading phase, only four injections a year are needed, which lowers the treatment noise in everyday life compared with therapies that require injections every two to four weeks.

The medication comes in a prefilled syringe or single-dose pen, designed to be used at home after training by healthcare professionals. Many users will appreciate avoiding regular clinic visits, though handling a biologic pen still takes a bit of courage at the beginning.

Efficacy and safety profile

Regulators approved Skyrizi for moderate to severe plaque psoriasis in adults based on robust phase 3 data, and the label has since been expanded to other indications such as psoriatic arthritis and Crohn’s disease in some regions, according to AbbVie’s product documentation.

The safety profile is consistent with other IL-23 inhibitors, with upper respiratory infections, headache and fatigue among the most commonly observed adverse reactions. Physicians also keep an eye on infection risk in general, as Skyrizi modulates the immune system over long periods.

Who Skyrizi is aimed at

Skyrizi aims at adults whose psoriasis is not adequately controlled with topical medications or conventional systemic treatments and who are ready for a targeted biologic. It is particularly interesting for patients who value strong, durable skin clearance and a low injection frequency.

Because it is a prescription-only biologic, the decision for Skyrizi is always made together with a dermatologist or gastroenterologist. Insurance coverage and national reimbursement rules strongly influence whether patients can access the drug in everyday practice.

Costs, access and competition

Skyrizi is clearly positioned as a high-end therapy, with biologic-level pricing that varies by country, insurance system and dose strength. In many markets, payers restrict access to patients who have failed other systemic therapies first.

In the biologic arena, Skyrizi competes with IL-17 and IL-23 inhibitors from other manufacturers that also promise very high skin clearance rates. Dosing rhythm, long-term data and physician familiarity often decide which product gets the prescription in daily practice.

What matters for investors

Skyrizi is one of AbbVie’s central growth drivers as the company navigates the gradual revenue erosion of its long-standing blockbuster Humira. Management repeatedly emphasizes the role of Skyrizi, alongside Rinvoq, in building the next wave of immunology sales.

Shares of AbbVie Inc. (US00287Y1091) trade on the New York Stock Exchange in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.